MYCO-003

**MYCO-003** is an investigational psychedelic **combination small-molecule** drug candidate from **Mydecine Innovations Group** being developed for **post-traumatic stress disorder and anxiety disorders**. Based on company disclosures and patent-related materials, it is a **psilocybin-based formulation** that combines a **serotonin receptor agonist** component with a **serotonin releasing agent** in an effort to improve psychedelic-assisted therapy by reducing treatment-emergent anxiety relative to psilocybin alone while potentially enhancing therapeutic efficacy. Publicly available descriptions indicate the program was supported by preclinical data and patent filings, but the exact chemical composition and specific serotonin-releasing co-ingredient have not been fully disclosed in the provided sources.